SSC
GMAB icon

Syverson Strege & Co’s Genmab GMAB Stock Holding History

Syverson Strege & Co’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-177
Closed -$6.68K – 287
2023
Q1 		$6.68K Buy
+177
New +$6.8K ﹤0.01% 298
2021
Q4 		– Sell
-135
Closed -$6K – 370
2021
Q3 		$6K Buy
+135
New +$6.06K ﹤0.01% 298

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Syverson Strege & Co's GMAB Position: Q2 2023 in Review

Syverson Strege & Co sold out of Genmab (GMAB) in Q2 2023, closing a stake of 177 shares — an estimated $6.68K sold.

Syverson Strege & Co first reported a position in GMAB in Q3 2021 and held it in 2 quarters. The position peaked at $6.68K in Q1 2023. 213 funds tracked by Wall St. Rank hold GMAB as of Q2 2023.

  • Syverson Strege & Co reported no remaining Genmab position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 177 Genmab shares in Q2 2023, an estimated $6.68K.
  • Syverson Strege & Co first reported a position in Genmab in Q3 2021 and held it in 2 quarters.
  • Syverson Strege & Co's Genmab position peaked at $6.68K in Q1 2023.
  • 213 funds tracked by Wall St. Rank held Genmab as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.